Personalised therapy in follicular lymphoma - is the dial turning?
Specht, L. Pavlovsky, A. Thompson, C. A. Kimby, E. de Jong, D. Nastoupil, L. J. Cottereau, A. S. Casulo, C. Sarkozy, C.
Specht, L.
Pavlovsky, A.
Thompson, C. A.
Kimby, E.
de Jong, D.
Nastoupil, L. J.
Cottereau, A. S.
Casulo, C.
Sarkozy, C.
Citations
Altmetric:
Abstract
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.
Description
Date
2023
Publisher
Collections
Keywords
Type
Article
Citation
Linton KM, Specht L, Pavlovsky A, Thompson CA, Kimby E, de Jong D, et al. Personalised therapy in follicular lymphoma - is the dial turning? Hematol Oncol. 2023 Jul 22. PubMed PMID: 37482955. Epub 2023/07/24. eng.